An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Taysha Gene Therapies to Participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Taysha Gene Therapies (Nasdaq: TSHA) announced participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference. The first chat, focusing on AAV-based Gene Therapy, will take place on March 14, 2022 at 11:00 am ET. The second chat is scheduled for March 15, 2022 at 1:20 pm ET. The events will feature the company's leadership, including the President, Founder, and CEO, and will be accessible via webcast on the Taysha corporate website.
Positive
None.
Negative
None.
President, Founder and Chief Executive Officer to participate in “AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape” fireside chat on March 14, 2022 at 11:00 am ET
Leadership team to participate in fireside chat at Oppenheimer’s 32nd Annual Virtual Healthcare Conference on March 15, 2022 at 1:20 pm ET
DALLAS--(BUSINESS WIRE)--
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference on Monday, March 14, 2022, and Tuesday, March 15, 2022.
A webcast of both events will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.
Fireside chat: AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape
Participants:
RA Session II, President, Founder and CEO
Date:
March 15, 2022
Time:
1:20 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and CEO
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
